Subscribe to RSS
DOI: 10.1055/s-0040-1722675
Recurrent Ataxia and Dystonia with Anti-Neurochondrin Autoantibodies
Funding None.We report the case of a 7-year-old boy who developed severe recurrent episodes of ataxia. Following the persistence of intrathecal pleocytosis and oligoclonal bands, autoimmune workup was performed, and anti-neurochondrin[1] antibodies in the cerebro-spinal fluid were discovered. Other investigations returned normal, no oncologic accompaniments were found.
Clinical examination identified cerebellar ataxia, cervical dystonia, choreic movements of the upper limbs, action tremor, opsoclonus, dysarthria, and akathisis ([Video 1]). Cognitive affective cerebellar syndrome, including neuropsychological impairment associated with significant emotional lability, was also found ([Table 1]).
Video 1 Walking test showing ataxic gait with deviation, instability especially during the turn around, increase space lift and excessive swinging arms; during the second part, the patient experiences difficulties in fine grasping and intention tremor. Note the presence of cervical dystonia (left laterocollis).
Quality:
Abbreviations: 6 MWT, 6 minutes walking test; KITAP, German test battery of attention performance; MFM, Mesure de la Fonction Motrice (measurement scale of motor function); NEPSY, neuropsychological assessment.
Initial corticosteroid therapy (intravenous methylprednisolone 30 mg/kg for 3 days) resulted in significant improvement. However, following the third relapse, a long-term corticotherapy with monthly intravenous methylprednisolone 500 mg/m2 was initiated. After 8 months, to avoid side effects, this treatment was replaced by mycophenolic acid. No relapse was observed since then. The child currently keeps slightly ataxic gait as well as significant cognitive impairment.
Autoimmune etiologies of the movement disorders are increasingly recognized, even in children.[2] [3] Unexplained repeated episodes of ataxia of subacute onset may require a workup with comprehensive neural IgG screening, especially since immune therapies seem more effective than what is observed in adults.[4]
Publication History
Received: 02 April 2020
Accepted: 19 April 2020
Article published online:
14 January 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Miske R, Gross CC, Scharf M. et al. Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2016; 4 (01) e307
- 2 Rommel FR, Miske R, Stöcker W, Arneth B, Neubauer BA, Hahn A. Chorea minor associated with anti-neurochondrin autoantibodies. Neuropediatrics 2017; 48 (06) 482-483
- 3 Weihua Z, Haitao R, Fang F, Xunzhe Y, Jing W, Hongzhi G. Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia. Cerebellum 2019; 18 (06) 1137-1142
- 4 Shelly S, Kryzer TJ, Komorowski L. et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm 2019; 6 (06) e612